

POLICY NAME	Orilissa (elagolix)	POLICY #	2679P
--------------------	---------------------	-----------------	-------

Criteria

Coverage Criteria

- ☐ Diagnosis of moderate to severe pain associated with endometriosis
- ☐ Age 18 years or older
- ☐ Prescribed by or in consultation with an obstetrician-gynecologist (women's health doctor)
- ☐ Documented failure, intolerance, or contraindication to a 3-month trial of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen AND oral contraceptives

Exclusion Criteria – Any of the following prevents coverage

- ☐ Orilissa will not be covered if the member is concurrently receiving therapy with a GnRH agonist or antagonist.
- ☐ Continued coverage is not allowed after the originally approved regimen is completed (150mg daily for 24 months OR 200mg twice daily for 6 months)
 - Orilissa is associated with dose-dependent irreversible decrease in bone mineral density